Acyclovir clinical pharmacology. An overview

Area of Science:

• Pharmacology
• Clinical Pharmacology
• Toxicology

Background:

• Acyclovir is a widely used antiviral medication.
• Understanding its pharmacokinetic and toxicologic profile is crucial for safe and effective clinical use.

Purpose of the Study:

• To review the current pharmacokinetic and toxicologic information on acyclovir from a clinical pharmacologist's perspective.
• To consolidate key data on acyclovir's absorption, distribution, metabolism, excretion, and toxicity.

Main Methods:

• Literature review of pharmacokinetic and toxicologic studies on acyclovir.
• Analysis of data from a clinical pharmacologist's viewpoint.

Main Results:

• Acyclovir pharmacokinetics is described by a two-compartment open model, with steady-state volume of distribution around two-thirds of body weight.
• Elimination half-life is approximately 3 hours with normal renal function, increasing to 18 hours with anuria; hemodialysis removes ~60% of the drug.
• Pharmacokinetics are dose-independent up to 15 mg/kg, with minimal protein binding (15%) and metabolism (15% of IV dose).
• Primary elimination is via glomerular filtration with some tubular secretion.
• Toxicity appears low, with noted side effects including local irritation and occasional transient glomerular dysfunction after bolus administration.

Conclusions:

• Acyclovir demonstrates predictable pharmacokinetics and acceptably low toxicity.
• Further research may be needed to fully establish all potential side effects.